United Therapeutics (UTHR) Receivables (2016 - 2025)
Historic Receivables for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $297.7 million.
- United Therapeutics' Receivables fell 1290.23% to $297.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $297.7 million, marking a year-over-year decrease of 1290.23%. This contributed to the annual value of $279.3 million for FY2024, which is 14.34% up from last year.
- Per United Therapeutics' latest filing, its Receivables stood at $297.7 million for Q3 2025, which was down 1290.23% from $379.3 million recorded in Q2 2025.
- United Therapeutics' Receivables' 5-year high stood at $379.3 million during Q2 2025, with a 5-year trough of $134.5 million in Q1 2023.
- Its 5-year average for Receivables is $246.6 million, with a median of $258.6 million in 2023.
- As far as peak fluctuations go, United Therapeutics' Receivables crashed by 2111.44% in 2023, and later soared by 12847.58% in 2024.
- United Therapeutics' Receivables (Quarter) stood at $198.7 million in 2021, then rose by 10.92% to $220.4 million in 2022, then grew by 26.54% to $278.9 million in 2023, then grew by 0.14% to $279.3 million in 2024, then grew by 6.59% to $297.7 million in 2025.
- Its Receivables was $297.7 million in Q3 2025, compared to $379.3 million in Q2 2025 and $322.0 million in Q1 2025.